Maxim Affirms Intellipharmaceutics (IPCI) at 'Buy' Following Q3 Results; Says Rexista NDA is Next Big Event
Tweet Send to a Friend
Maxim reaffirms Intellipharmaceutics International (Nasdaq: IPCI) at Buy with a price target of $6 following Q3 results issued Thursday night.Jason ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
